Literature DB >> 2088764

Pharmacokinetics of nifedipine derived from a new retard tablet formulation.

A Avgerinos1, J W Gorrod.   

Abstract

A nifedipine retard tablet formation (Glopir, 20mg) was developed to reduce the number of daily doses required in the treatment of hypertension. The plasma pharmacokinetics of this oral formulation were examined, in a single study, on 12 healthy volunteers. Single 20 mg doses of nifedipine retard tablet (Glopir, GAP & Co. Athens, Greece) were given after an overnight fast and 10 blood samples were drawn during the first 24 h after administration. Plasma concentrations of nifedipine were measured by high performance liquid chromatography. The mean peak plasma nifedipine concentration was 27.6 ng/ml at a maximum time of 24 h, after tablet ingestion. The mean apparent nifedipine elimination half-life was 16.0 +/- 7.5 h and the mean area under the plasma concentration time curve (0-24 h) 404.1 +/- 134.0 ng/ml.h. The data suggest that the tablet form has properties of a sustained-release preparation, with slow accumulation and elimination phases and can appropriately be given in a twice-daily regimen.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2088764     DOI: 10.1007/BF03190215

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  27 in total

1.  [The effect of cardiac glycosides on the visual system of man measured with cortical evoked potentials].

Authors:  D Johnson; R Hopf; A Frauendorf; B G Woodcock; F Mujtaba
Journal:  Arzneimittelforschung       Date:  1986-02

2.  Haemodynamic effects of a calcium antagonistic agent (nifedipine) in hypertension: therapeutic implications.

Authors:  C Bartorelli; F Magrini; P Moruzzi; M T Olivari; A Polese; C Fiorentini; M Guazzi
Journal:  Clin Sci Mol Med Suppl       Date:  1978-12

3.  Efficacy and safety of sublingual nifedipine in hypertensive emergencies.

Authors:  A G Ellrodt; M J Ault; M S Riedinger; G H Murata
Journal:  Am J Med       Date:  1985-10-11       Impact factor: 4.965

Review 4.  Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem.

Authors:  P D Henry
Journal:  Am J Cardiol       Date:  1980-12-01       Impact factor: 2.778

5.  Antihypertensive effect of (4-2'-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarbonic acid dimethylester (Nifedipine, Bay-a 1040), a new coronary dilator.

Authors:  M Murakami; E Murakami; N Takekoshi; M Tsuchiya; T Kin
Journal:  Jpn Heart J       Date:  1972-03

6.  Nifedipine: kinetics and dynamics in healthy subjects.

Authors:  C H Kleinbloesem; P van Brummelen; J A van de Linde; P J Voogd; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1984-06       Impact factor: 6.875

7.  Nifedipine therapy for coronary-artery spasm. Experience in 127 patients.

Authors:  E Antman; J Muller; S Goldberg; R MacAlpin; M Rubenfire; B Tabatznik; C S Liang; F Heupler; S Achuff; N Reichek; E Geltman; N Z Kerin; R K Neff; E Braunwald
Journal:  N Engl J Med       Date:  1980-06-05       Impact factor: 91.245

8.  Acute antihypertensive effect and pharmacokinetics of a tablet preparation of nifedipine.

Authors:  O Banzet; J N Colin; M Thibonnier; E Singlas; J M Alexandre; P Corvol
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Nifedipine in the treatment of hypertension: report of a double-blind controlled trial.

Authors:  S Bayley; R J Dobbs; B F Robinson
Journal:  Br J Clin Pharmacol       Date:  1982-10       Impact factor: 4.335

10.  Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension.

Authors:  N Beer; I Gallegos; A Cohen; N Klein; E Sonnenblick; W Frishman
Journal:  Chest       Date:  1981-05       Impact factor: 9.410

View more
  2 in total

Review 1.  Novel oral drug formulations. Their potential in modulating adverse effects.

Authors:  A T Florence; P U Jani
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

Review 2.  The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.

Authors:  J S Grundy; R T Foster
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.